News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pozen, Inc. (POZN) Receives Positive News On MT 100 In The U.K.


10/19/2005 5:12:33 PM

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jan. 26, 2005--POZEN Inc. (NASDAQ: POZN) announced today that it has received a letter from the Committee on Safety of Medicines (CSM), the Advisory Group to the United Kingdom's (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), agreeing to advise the MHRA that a marketing authorization be granted for MT 100 in the UK, provided that POZEN supplies additional information and meets certain conditions outlined in the letter. Although the MHRA is not bound by the CSM's recommendation, POZEN believes that the MHRA typically agrees with the CSM's opinions. POZEN believes that it can provide the additional information and address all of the conditions set forth in the letter and plans to respond to the letter within 30 days.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES